vs
雅培（ABT）与通用电气医疗（OPCH）财务数据对比。点击上方公司名可切换其他公司
雅培的季度营收约是通用电气医疗的8.0倍（$11.5B vs $1.4B）。雅培净利率更高（15.5% vs 3.6%，领先11.9%）。通用电气医疗同比增速更快（12.2% vs 4.4%）。雅培自由现金流更多（$2.6B vs $130.2M）。过去两年通用电气医疗的营收复合增速更高（13.0% vs 7.2%）
雅培是总部位于美国伊利诺伊州雅培园的跨国医疗健康企业，业务覆盖美国境外市场药品销售、诊断产品、营养产品及医疗器械等板块，在全球医疗健康领域拥有较高的行业知名度与广泛的市场覆盖。
通用电气医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，旗下设四大业务板块：医学影像（含分子成像、CT、磁共振、女性健康筛查及X线设备）、超声、患者护理解决方案（覆盖远程患者监测、麻醉呼吸护理、心脏病诊断、婴儿护理等）及制药相关业务。
ABT vs OPCH — 直观对比
营收规模更大
ABT
是对方的8.0倍
$1.4B
营收增速更快
OPCH
高出7.8%
4.4%
净利率更高
ABT
高出11.9%
3.6%
自由现金流更多
ABT
多$2.5B
$130.2M
两年增速更快
OPCH
近两年复合增速
7.2%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $11.5B | $1.4B |
| 净利润 | $1.8B | $51.8M |
| 毛利率 | 57.0% | 19.0% |
| 营业利润率 | 19.6% | 5.9% |
| 净利率 | 15.5% | 3.6% |
| 营收同比 | 4.4% | 12.2% |
| 净利润同比 | -80.8% | -3.8% |
| 每股收益（稀释后） | $1.01 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTOPCH
| Q4 25 | $11.5B | — | ||
| Q3 25 | $11.4B | $1.4B | ||
| Q2 25 | $11.1B | $1.4B | ||
| Q1 25 | $10.4B | $1.3B | ||
| Q4 24 | $11.0B | $1.3B | ||
| Q3 24 | $10.6B | $1.3B | ||
| Q2 24 | $10.4B | $1.2B | ||
| Q1 24 | $10.0B | $1.1B |
净利润ABTOPCH
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.6B | $51.8M | ||
| Q2 25 | $1.8B | $50.5M | ||
| Q1 25 | $1.3B | $46.7M | ||
| Q4 24 | $9.2B | $60.1M | ||
| Q3 24 | $1.6B | $53.9M | ||
| Q2 24 | $1.3B | $53.0M | ||
| Q1 24 | $1.2B | $44.8M |
毛利率ABTOPCH
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | 19.0% | ||
| Q2 25 | 56.4% | 19.0% | ||
| Q1 25 | 56.9% | 19.7% | ||
| Q4 24 | 55.0% | 21.3% | ||
| Q3 24 | 55.8% | 20.1% | ||
| Q2 24 | 55.6% | 20.3% | ||
| Q1 24 | 55.2% | 20.8% |
营业利润率ABTOPCH
| Q4 25 | 19.6% | — | ||
| Q3 25 | 18.1% | 5.9% | ||
| Q2 25 | 18.4% | 5.8% | ||
| Q1 25 | 16.3% | 5.9% | ||
| Q4 24 | 17.4% | 6.9% | ||
| Q3 24 | 17.5% | 6.7% | ||
| Q2 24 | 16.1% | 6.6% | ||
| Q1 24 | 13.9% | 6.0% |
净利率ABTOPCH
| Q4 25 | 15.5% | — | ||
| Q3 25 | 14.5% | 3.6% | ||
| Q2 25 | 16.0% | 3.6% | ||
| Q1 25 | 12.8% | 3.5% | ||
| Q4 24 | 84.1% | 4.8% | ||
| Q3 24 | 15.5% | 4.2% | ||
| Q2 24 | 12.5% | 4.3% | ||
| Q1 24 | 12.3% | 3.9% |
每股收益（稀释后）ABTOPCH
| Q4 25 | $1.01 | — | ||
| Q3 25 | $0.94 | $0.32 | ||
| Q2 25 | $1.01 | $0.31 | ||
| Q1 25 | $0.76 | $0.28 | ||
| Q4 24 | $5.26 | $0.36 | ||
| Q3 24 | $0.94 | $0.31 | ||
| Q2 24 | $0.74 | $0.30 | ||
| Q1 24 | $0.70 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.9B | $309.8M |
| 总债务越低越好 | $12.9B | $1.2B |
| 股东权益账面价值 | $52.1B | $1.4B |
| 总资产 | $86.7B | $3.5B |
| 负债/权益比越低杠杆越低 | 0.25× | 0.86× |
8季度趋势，按日历期对齐
现金及短期投资ABTOPCH
| Q4 25 | $8.9B | — | ||
| Q3 25 | $7.7B | $309.8M | ||
| Q2 25 | $7.3B | $198.8M | ||
| Q1 25 | $6.8B | $171.4M | ||
| Q4 24 | $8.0B | $412.6M | ||
| Q3 24 | $7.8B | $483.0M | ||
| Q2 24 | $7.2B | $376.9M | ||
| Q1 24 | $6.7B | $219.5M |
总债务ABTOPCH
| Q4 25 | $12.9B | — | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $14.1B | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
股东权益ABTOPCH
| Q4 25 | $52.1B | — | ||
| Q3 25 | $51.0B | $1.4B | ||
| Q2 25 | $50.6B | $1.4B | ||
| Q1 25 | $48.8B | $1.4B | ||
| Q4 24 | $47.7B | $1.4B | ||
| Q3 24 | $39.8B | $1.4B | ||
| Q2 24 | $39.3B | $1.4B | ||
| Q1 24 | $38.8B | $1.4B |
总资产ABTOPCH
| Q4 25 | $86.7B | — | ||
| Q3 25 | $84.2B | $3.5B | ||
| Q2 25 | $84.0B | $3.4B | ||
| Q1 25 | $81.4B | $3.3B | ||
| Q4 24 | $81.4B | $3.4B | ||
| Q3 24 | $74.4B | $3.4B | ||
| Q2 24 | $73.0B | $3.3B | ||
| Q1 24 | $72.5B | $3.2B |
负债/权益比ABTOPCH
| Q4 25 | 0.25× | — | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.82× | ||
| Q4 24 | 0.30× | 0.79× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.79× | ||
| Q1 24 | — | 0.74× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $139.4M |
| 自由现金流经营现金流 - 资本支出 | $2.6B | $130.2M |
| 自由现金流率自由现金流/营收 | 22.9% | 9.1% |
| 资本支出强度资本支出/营收 | 6.0% | 0.6% |
| 现金转化率经营现金流/净利润 | 1.87× | 2.69× |
| 过去12个月自由现金流最近4个季度 | $7.4B | $220.7M |
8季度趋势，按日历期对齐
经营现金流ABTOPCH
| Q4 25 | $3.3B | — | ||
| Q3 25 | $2.8B | $139.4M | ||
| Q2 25 | $2.0B | $90.3M | ||
| Q1 25 | $1.4B | $-7.2M | ||
| Q4 24 | $2.9B | $36.1M | ||
| Q3 24 | $2.7B | $160.4M | ||
| Q2 24 | $2.0B | $195.7M | ||
| Q1 24 | $1.0B | $-68.8M |
自由现金流ABTOPCH
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | $130.2M | ||
| Q2 25 | $1.5B | $81.2M | ||
| Q1 25 | $933.0M | $-16.6M | ||
| Q4 24 | $2.1B | $25.8M | ||
| Q3 24 | $2.1B | $150.7M | ||
| Q2 24 | $1.4B | $185.9M | ||
| Q1 24 | $627.0M | $-74.6M |
自由现金流率ABTOPCH
| Q4 25 | 22.9% | — | ||
| Q3 25 | 20.2% | 9.1% | ||
| Q2 25 | 13.9% | 5.7% | ||
| Q1 25 | 9.0% | -1.2% | ||
| Q4 24 | 19.6% | 2.0% | ||
| Q3 24 | 20.2% | 11.8% | ||
| Q2 24 | 13.8% | 15.1% | ||
| Q1 24 | 6.3% | -6.5% |
资本支出强度ABTOPCH
| Q4 25 | 6.0% | — | ||
| Q3 25 | 4.4% | 0.6% | ||
| Q2 25 | 4.5% | 0.6% | ||
| Q1 25 | 4.7% | 0.7% | ||
| Q4 24 | 6.6% | 0.8% | ||
| Q3 24 | 5.2% | 0.8% | ||
| Q2 24 | 5.1% | 0.8% | ||
| Q1 24 | 4.0% | 0.5% |
现金转化率ABTOPCH
| Q4 25 | 1.87× | — | ||
| Q3 25 | 1.70× | 2.69× | ||
| Q2 25 | 1.15× | 1.79× | ||
| Q1 25 | 1.07× | -0.15× | ||
| Q4 24 | 0.31× | 0.60× | ||
| Q3 24 | 1.64× | 2.98× | ||
| Q2 24 | 1.51× | 3.69× | ||
| Q1 24 | 0.84× | -1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABT
暂无分部数据
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
